title: Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe.
authors.affiliation: Institute for Diagnosis and Treatment of Lipid Disorders (ATHOS), Department of Nuclear Medicine, University of Vienna, Austria. helmut.sinzinger@akh-wien.ac.at
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
authors.forename: F
authors.initials: F
authors.lastname: Chehne
authors.forename: A
authors.initials: A
authors.lastname: Ferlitsch
authors.forename: A
authors.initials: A
authors.lastname: Oguogho
mesh_terms: D000707:Anaphylaxis / Q000517:prevention & control; D057911:Angiotensin Receptor Antagonists; D001781:Blood Component Removal / Q000379:methods / Q000592:standards*; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000097:blood / Q000187:drug effects; D003257:Consumer Product Safety; D016264:Dextran Sulfate; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy / Q000628:therapy; D008077:Lipoproteins, LDL; D008297:Male; D008875:Middle Aged
chemical_list: D057911:Angiotensin Receptor Antagonists; D008077:Lipoproteins, LDL; D016264:Dextran Sulfate; D001920:Bradykinin